TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
CELU

Celularity Inc

Healthcare · Biotechnology

0.8001$ -5.8% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Celularity Inc (CELU)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 68.9% of the shares are freely tradable; institutional investors hold 12.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 12.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 37.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 68.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 32Mio.

Largest Shareholders

Institutions

Institutions CELU
Name Stake (%) Shares Change (%) Date
C V Starr & Co Inc 2.35 764,069 +0.0 06/30/2026
Vanguard Capital Management, LLC 1.91 621,105 +0.0 06/30/2026
Geode Capital Management, LLC 0.52 167,150 -12.5 06/30/2026
Citadel Advisors Llc 0.31 99,054 +0.0 06/30/2026
Vanguard Fiduciary Trust Co 0.25 79,874 +0.0 06/30/2026
BlackRock Inc 0.24 76,359 -40.1 06/30/2026
State Street Corp 0.18 57,830 +0.0 06/30/2026
HRT FINANCIAL LLC 0.17 56,591 +342.7 06/30/2026

Funds

Funds CELU
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.40 455,049 +0.0 09/30/2026
Fidelity Extended Market Index 0.27 86,956 -0.5 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?